{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-085661","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.512702+00:00","generated_at":"2026-06-24T05:14:14.701522+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avenue Therapeutics appoints Alexandra MacLean, M.D. as CEO","bullets":["Alexandra MacLean, M.D., appointed CEO effective August 1, 2022.","Dr. MacLean previously an Entrepreneur in Residence at Fortress Biotech (FBIO).","She will receive an annual cash salary of $332,200; no employment agreement yet.","David Jin ends interim CEO role, remains interim CFO and COO.","No family relationships or transactions requiring disclosure under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-085661","json":"https://secwatch.observer/filing/0001104659-22-085661.json","markdown":"https://secwatch.observer/filing/0001104659-22-085661.md","text":"https://secwatch.observer/filing/0001104659-22-085661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/tm2222416d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T05:14:14.701522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2998da2eae","claim":"David Jin changed role as Interim Chief Executive Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"With the appointment of Dr. MacLean as the new Chief Executive Officer, Mr. David Jin will end his term as interim Chief Executive Officer and will continue his responsibilities as Interim Chief Financial Officer and Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ended his term as"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c7f8d7aec1","claim":"Alexandra MacLean, M.D. was appointed as Chief Executive Officer at AVENUE THERAPEUTICS, INC..","evidence_excerpt":"On August 1, 2022, the Board of Directors of Avenue Therapeutics, Inc. (the “ Company ”) appointed Alexandra MacLean, M.D., to serve as the Company’s Chief Executive Officer, with immediate effect.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922085661/0001104659-22-085661-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}